A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: A review of CDK inhibitors

Mariane Teodoro Fernandes, Jacob J. Adashek, Carmelia Maria Noia Barreto, Ana Cláudia Barbin Spinosa, Barbara de Souza Gutierres, Gilberto Lopes, Auro del Giglio, Pedro Nazareth Aguiar

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. All of the approved drugs exhibit progression-free survival benefit when compared to standard of care and generally have less adverse events compared to traditional chemotherapeutic options. The treatment of HR+/HER2- advanced breast cancer is a continuously evolving landscape, and the addition of CDK4/6 inhibitors is the newest mechanism for treatment. In this review, we summarize all available data, highlight the unanswered questions, and discuss pharmacological differences between each CDK4/6 inhibitor.

Original languageEnglish (US)
Article number212555
JournalDrugs in Context
Volume7
DOIs
StatePublished - 2018

Keywords

  • Breast cancer
  • Cyclin-dependent kinase 4
  • Cyclin-dependent kinase 6
  • Endocrine therapy
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: A review of CDK inhibitors'. Together they form a unique fingerprint.

Cite this